Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
A Phase 2a Double-Blind, Dose-optimizing Study to Evaluate the Immunogenicity of Hantaan/Puumala Virus DNA Vaccine Administered to Healthy Adult Volunteers by Electroporation for Prevention of Hemorrhagic Fever With Renal Syndrome
Sponsor: Ichor Medical Systems Incorporated
Listed as NCT02116205, this PHASE2 trial focuses on Hemorrhagic Fever With Renal Syndrome and remains completed. Sponsored by Ichor Medical Systems Incorporated, it has been updated 12 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2021 — Oct 2021 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
Apr 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ichor Medical Systems Incorporated
- U.S. Army Medical Research and Development Command
- US Army Medical Research Institute of Infectious Diseases
- United States Army Medical Materiel Development Activity
- Walter Reed Army Institute of Research (WRAIR)
For direct contact, visit the study record on ClinicalTrials.gov .